Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ...

Valmet's Shareholders' Nomination Board updates its proposal for the composition and remuneration of the Board of Directors Valmet Oyj's stock exchange release on January 27, 2025 at 2:00 p.m. EET ...

Trinity Capital Inc.  ("Trinity Capital"), a leading alternative asset manager, today announced the commitment of $30 million in growth capital to Elucent Medical ("Elucent"), a pioneering medical ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...